MARKET

CVKD

CVKD

Cadrenal Therape
NASDAQ
11.10
+2.24
+25.28%
After Hours: 10.84 -0.26 -2.34% 19:47 12/04 EST
OPEN
9.66
PREV CLOSE
8.86
HIGH
11.58
LOW
9.66
VOLUME
179.87K
TURNOVER
--
52 WEEK HIGH
22.90
52 WEEK LOW
8.12
MARKET CAP
23.04M
P/E (TTM)
-1.4190
1D
5D
1M
3M
1Y
5Y
1D
Cadrenal Therapeutics Files Initial Statement of Beneficial Ownership for Director Lee Scott Golden
Reuters · 1d ago
Cadrenal Therapeutics Appoints Dr. Golden to Board
TipRanks · 3d ago
*Cadrenal Therapeutics Golden is Currently Executive Vice Pres, Chief Medical Officer at PTC Therapeutics >CVKD
Dow Jones · 3d ago
*Cadrenal Therapeutics Appoints Lee Golden to Bd of Directors >CVKD
Dow Jones · 3d ago
CADRENAL THERAPEUTICS APPOINTS DR. LEE GOLDEN TO BOARD OF DIRECTORS
Reuters · 3d ago
Press Release: Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors
Dow Jones · 3d ago
Weekly Report: what happened at CVKD last week (1124-1128)?
Weekly Report · 3d ago
Weekly Report: what happened at CVKD last week (1117-1121)?
Weekly Report · 11/24 09:19
More
About CVKD
Cadrenal Therapeutics, Inc. is a biopharmaceutical company focused on developing transformative therapeutics to overcome the gaps in anticoagulation therapy. The Company’s lead investigational product is tecarfarin, a novel oral vitamin K antagonist anticoagulant that is designed to address unmet needs in anticoagulation therapy. Tecarfarin is a reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Tecarfarin has orphan drug designation (ODD) for advanced heart failure patients with implanted mechanical circulatory support devices, including left ventricular assisted devices (LVADs). The Company also has ODD and fast-track status for tecarfarin in end-stage kidney disease and atrial fibrillation (ESKD+AFib). It also includes Frunexian, a Phase 2-ready IV Factor XIa agent for acute anticoagulation and EP-7327 is a ready oral small molecule candidate for chronic indications.

Webull offers Cadrenal Therapeutics Inc stock information, including NASDAQ: CVKD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CVKD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CVKD stock methods without spending real money on the virtual paper trading platform.